RKDA Arcadia Biosciences, Inc.
Price Chart
Executive Summary
Arcadia Biosciences announces a private placement of ~3.88M common shares (or pre-funded warrants) plus two series of preferred investment options for ~$4M gross proceeds, priced at $1.03 per share at-the-market under Nasdaq rules. This highly dilutive offering on a $2M market cap signals acute cash need; the prior 33% win rate on RKDA reports and negative T+20 calibration reinforce a bearish outlook.
Key Financial Metrics
Actionable Insight
Expect heavy selling pressure as market prices in extreme dilution and the resale registration clears. The Series A-2 options are exercisable immediately upon registration, creating near-term overhang. Risk of continued cash burn and further raises is high given the company's prior disclosure of needing additional funding. Traders should avoid long exposure and consider protective puts or short positions if liquidity permits.
Key Facts
- 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options for up to 3,883,496 shares each, all priced at $1.03/share.
- Gross proceeds of ~$4M before fees; net proceeds for working capital and general corporate purposes.
- Series A-1 options exercisable at $0.91/share after stockholder approval, expiring 5 years from approval; Series A-2 options exercisable at $0.91/share immediately, expiring 24 months from resale registration effective date.
- Offering is a private placement under Section 4(a)(2)/Reg D, with a resale registration statement to be filed.
- Expected closing on or about June 12, 2026; H.C. Wainwright & Co. as exclusive placement agent.
- Market cap of only $2M; offering size ($4M) equals 200% of market cap, implying massive potential dilution.
Financial Impact
Gross proceeds ~$4M on a $2M market cap; share count potentially tripling. Dilution severe even without including the two tranches of investment options.
Risk Factors
- Dilution could exceed 200% of current shares outstanding, crushing per-share metrics.
- Series A-1 and A-2 investment options add additional overhang; A-2 exercisable immediately upon resale registration.
- Company flagged it may need additional future funding in its 10-K — this offering may not be the last.
- Historical model calls on RKDA show poor T+20 alpha; net segment alpha is -2.84% after costs — consistent with bearish outcome here.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310862 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 13, 2026
today
|
Press Release
| — | awaiting T+5 | — | — |
|
Jun 12, 2026
1d ago
|
Press Release
| $1.20 awaiting T+5 | awaiting T+5 | — | $1.03 (+14.17%) |
|
May 14, 2026
29d ago
|
8-K
| $0.9560 $0.9190 | ▲ +3.87% | ▲ +4.83% | $1.03 (−7.74%) |
|
Apr 30, 2026
6w ago
|
10-K/A
| $1.12 $1.07 | ▼ −4.46% | ▼ −6.81% | $1.03 (−8.04%) |
|
Apr 3, 2026
10w ago
|
8-K
| $1.30 $1.33 | ▼ −1.92% | ▲ +2.21% | $1.03 (+20.77%) |
|
Mar 26, 2026
11w ago
|
Press Release
| $1.47 $1.30 | ▼ −11.56% | ▼ −15.43% | $1.03 (−29.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access